Full text is available at the source.
Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma
Using Tiny Particles to Deliver Temozolomide and PD-L1 Silencing Molecules to Change Drug-Resistant and Immune-Suppressing Environments in Brain Tumors
AI simplified
Abstract
TMZ/siPD-L1@GLPN/dsb significantly inhibited the growth of orthotopic TMZ-resistant glioblastoma and extended survival time in rats.
- A nanoparticle formulation was created to deliver both temozolomide and siPD-L1 to resistant glioblastoma tissue.
- This formulation increased the percentage of T cells producing interferon-gamma, enhancing T-cell activity against the tumor.
- It also decreased the presence of regulatory T cells, which are associated with immune suppression.
- The treatment reduced the expression of a protein linked to DNA repair, potentially increasing sensitivity to temozolomide.
- Overall, the nanoparticle approach may help overcome resistance and improve outcomes in glioblastoma therapy.
AI simplified